Loading stock data…
Ultragenyx Pharmaceutical Inc. (RARE)
$30.68-0.09 (-0.29%)
Market ClosedLast close Jun 29
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ultragenyx Pharmaceutical Inc. in the Healthcare sector is trading at $30.68 with a market capitalization of $2.2B. Wall Street consensus targets $52.05 (19 analysts), implying a +69.7% move over the next 12 months. The stock is currently 28% below its 52-week high of $42.37, remaining 13.8% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +69.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $136.00M↓ | $207.28M↑ | $159.93M↓ | $166.50M↑ | $139.00M |
| Gross Profit | $106.00M↓ | $177.93M↑ | $131.94M↓ | $143.49M↑ | $110.00M |
| Operating Income | -$169.00M↓ | -$113.28M↑ | -$170.89M↓ | -$107.89M↑ | -$143.00M |
| Net Income | -$185.00M↓ | -$128.56M↑ | -$180.41M↓ | -$114.95M↑ | -$151.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, E...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.21B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.39
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
258.02%
Volume
Today's trading volume
3.92M
Recent News
Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?
Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here is Why Ultragenyx Pharmaceutical (RARE) is One of the Best Buy-the-Dip Stocks
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the 12 best buy-the-dip stocks to invest in now. As of June 5 closing, the consensus sentiment around Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) remained strongly bullish. Based on a median one-year target price of $51.87, the stock offers more than 122% upside. Back on May 21, Kristen Kluska from […]
How The Ultragenyx Pharmaceutical (RARE) Investment Story Is Shifting With New Data And Street Views
Ultragenyx Pharmaceutical’s updated fair value estimate now sits at US$52.05 per share, a slight change from the prior US$52.45 target that reframes expectations around the stock. This move comes as Street research remains split, with some analysts lifting targets on optimism around GTX-102 while others trim forecasts or downgrade the stock after reassessing pipeline risk and execution. As you read on, you will see how these shifting targets and opinions can shape the way you track the...
Institutional Confidence in GTX-102 Fuels Optimism for Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 21, Cantor Fitzgerald analyst Kristen Kluska maintained an Overweight rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and raised the price target from $84 to $96. This valuation adjustment is based on the growing institutional confidence in […]
Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.